


ASCO24

TOP TEN BY ONCOALERT

MELANOMA



OncoAlert³⁶⁰
Oncology For Colleagues By Colleagues

LBA2

NEOADJUVANT NIVOLUMAB PLUS IPILIMUMAB VERSUS ADJUVANT NIVOLUMAB IN MACROSCOPIC, RESECTABLE STAGE ILL MELANOMA: THE PHASE 3 NADINA TRIAL.

**LBA
9501**

PHASE 3 STUDY (PIVOTAL) OF NEOADJUVANT INTRALESIONAL DAROMUN VS. IMMEDIATE SURGERY IN FULLY RESECTABLE MELANOMA WITH REGIONAL SKIN AND/OR NODAL METASTASES.

**LBA
9503**

COMBINATION OF ENCORAFENIB AND BINIMETINIB FOLLOWED BY IPILIMUMAB AND NIVOLUMAB VERSUS IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH ADVANCED BRAF-V600E/K-MUTATED MELANOMA: (EBIN).

9504

EFFICACY AND SAFETY OF TRIPLET NIVOLUMABO, RELATLIMAO, AND IPILIMUMAB (NIVO + RELA + IPI) IN ADVANCED MELANOMA: RESULTS FROM RELATIVITY-048.

9507

PHASE 1 SAFETY AND EFFICACY OF IMC-F106C, A PRAME X CD3 IMMTAC BISPECIFIC, IN POST-CHECKPOINT CUTANEOUS MELANOMA (CM).

9508

SAFETY AND EFFICACY OF FIRST-IN-CLASS CXCR1/2 INHIBITOR SX-682 IN COMBINATION WITH PEMBROLIZUMAB (PEM) IN PATIENTS (PTS) WITH METASTATIC MELANOMA (MMEL) WITH DISEASE PROGRESSION ON ANTI-PD-1 THERAPY.

9505

EFFICACY AND SAFETY OF LIFILEUCEL, AN AUTOLOGOUS TIL CELL THERAPY, AND PEMBROLIZUMAB IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-NAIVE UNRESECTABLE OR METASTATIC MELANOMA: UPDATED RESULTS FROM LOV-COM-202 COHORT 1A.

9509

PHASE II MULTI-CENTER STUDY OF ADJUVANT NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH HIGH-RISK UVEAL MELANOMA (HCRN MEL17-309).

9517

EFFICACY AND SAFETY OF RP1 COMBINED WITH NIVOLUMAB IN PATIENTS WITH ANTI-PD-1-FAILED MELANOMA FROM THE IGNYTE CLINICAL TRIAL.

9515

OBX-115, AN INTERLEUKIN 2 (IL2)-SPARING ENGINEERED TUMOR-INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY, IN PATIENTS (PTS) WITH IMMUNE CHECKPOINT INHIBITOR (ICI)-RESISTANT UNRESECTABLE OR METASTATIC MELANOMA.

**LBA
9512**

INDIVIDUALIZED NEOANTIGEN THERAPY MRNA-4157 (V940) PLUS PEMBROLIZUMAB IN RESECTED MELANOMA: 3-YEAR UPDATE FROM THE MRNA-4157-P201 (KEYNOTE-942) TRIAL.

WWW.ONCOALERT360.COM

Leads



Dr Wong
Med Onc



Dr Morgan
Clin Onc

Faculty



Dr Betof Warner
Med Onc